Company intelligence / Profile preview

SangStat Medical

Fremont, California, United States

Ownership: Private
Employees: ~300
Development stage: Other

Overview

SangStat's most successful commercial product was Thymoglobulin (antithymocyte globulin), approved for the treatment of kidney transplant rejection, with additional indications explored in bone marrow transplant and autoimmune disease. Clinical-stage candidates included RDP58 (an anti-inflammatory peptide) for ulcerative colitis and Crohn's disease, and other biologics for immunomodulation[2][9][10].

Therapeutic areas: HematologyImmunologyDermatologyGastroenterology
Modalities: Small moleculeBiologicPeptidesPolyclonal antibodyDevice
Industry: Biotech

Partnerships

Abgenix, Inc.

Beyond the preview

Go deeper on SangStat Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SangStat Medical.

Explore the full profile